期刊文献+
共找到4篇文章
< 1 >
每页显示 20 50 100
Gastrointestinal stromal tumors and second primary malignancies before and after the introduction of imatinib mesylate 被引量:1
1
作者 Jacopo Giuliani andrea bonetti 《Chinese Journal of Cancer Research》 SCIE CAS CSCD 2013年第5期486-487,共2页
Gastrointestinal stromal tumor (GIST) is the most common mesenchymal malignancy of the gastrointestinal tract.GISTs may coexist with different types of cancer,either synchronous or metachronous (1).Most GISTs deve... Gastrointestinal stromal tumor (GIST) is the most common mesenchymal malignancy of the gastrointestinal tract.GISTs may coexist with different types of cancer,either synchronous or metachronous (1).Most GISTs develop in a sporadic fashion,but familial occurrence,such as neurofibromatosis and Carney-triad,has also been reported (2).The overall frequency of second tumors in different series varied from 4.5% to 33%.The most frequent types of GIST-associated cancers were gastrointestinal carcinomas (47%),lymphoma/leukemia (7%),carcinomas of prostate (9%),breast (7%),kidney (6%),lung (5%),female genital tract (5%),carcinoid tumors (3%),soft tissue and bone sarcomas (3%),malignant melanoma (2%) and seminoma (1%) (1,3-5). 展开更多
关键词 GIST Gastrointestinal stromal tumors and second primary malignancies before and after the introduction of imatinib mesylate
下载PDF
Towards a standardisation for digital inputs and outputs of protection functions in IEC 60255 series 被引量:1
2
作者 Volker Leitloff Hao Chen +4 位作者 Dehui Chen andrea bonetti Lei Xu Ahmed Mohamed Carl Byman 《Protection and Control of Modern Power Systems》 2022年第1期382-392,共11页
Fully digitalized substations using IEC 61850 process bus are being introduced all over the world.Numerous utilities have featured pilot projects,demonstrators or even industrial scale deployment of these Fully Digita... Fully digitalized substations using IEC 61850 process bus are being introduced all over the world.Numerous utilities have featured pilot projects,demonstrators or even industrial scale deployment of these Fully Digital Protection,Auto-mation and Control Systems(FD-PACS).Product standards such as profiles for Instrument Transformers have been developed and published(IEC 61869-6 and IEC 61869-9 by TC 38-Instrument Transformers).This raises the question about the standards for digitally interfaced protection functions.In 2016,IEC TC 95(Measuring relays and protection equipment)charged a working group to investigate this subject and to elaborate recommendations concerning requirements and testing of protection IED with digital inputs and outputs for protection standards(IEC 60255-1xx series).For protection functions,publisher/subscriber based data streams are supposed to comply with IEC 61850 and IEC 61869 standards.This holds in particular for Sampled Values(SV)representing energising inputs of the protection function,and is also applicable to Generic Object Oriented Substation Event(GOOSE)which can be used for input or output of protection functions.Quality attributes of published data depend on the operational and connection status of the function and the hosting IED.In addition,protection functions have to take into account the information regarding the time synchronisation of the received SV and other parameters.This paper gives an overview of these features and the proposed way to take them into account in the IEC 60255 standard series.It describes the progress of WG 2 and relates it to existing standardization documents. 展开更多
关键词 Process bus Protection function Digital interface SAMU LPIT STANDARDS IEC 61850
原文传递
Cost-effectiveness of Osimertinib in activating epidermal growth factor receptor gene(EGFR)-mutations in first-line for advanced non-small cell lung cancer 被引量:2
3
作者 Jacopo Giuliani andrea bonetti 《Cancer Drug Resistance》 2021年第3期740-744,共5页
The introduction of first-or second-generation epidermal growth factor receptor gene(EGFR)tyrosine kinase inhibitors(TKIs)in chemonaive patients with advanced non-small cell lung cancer(NSCLC)has radically changed the... The introduction of first-or second-generation epidermal growth factor receptor gene(EGFR)tyrosine kinase inhibitors(TKIs)in chemonaive patients with advanced non-small cell lung cancer(NSCLC)has radically changed the treatment in this molecular subgroup,with an improvement in progression-free survival(PFS)compared to standard chemotherapy[1]. 展开更多
关键词 NSCLC activating EGFR-mutations first-line treatment TKIs cost of drugs
原文传递
History of intraperitoneal platinum drug delivery for ovarian cancer and its future applications 被引量:1
4
作者 Franco Muggia andrea bonetti 《Cancer Drug Resistance》 2021年第2期453-462,共10页
Intraperitoneal(IP)delivery of cisplatin was developed in the 1970s based on a strong pharmacologic rationale and rodent models.Its advantage over intravenous(IV)administration was supported initially by observational... Intraperitoneal(IP)delivery of cisplatin was developed in the 1970s based on a strong pharmacologic rationale and rodent models.Its advantage over intravenous(IV)administration was supported initially by observational studies in treating recurrent ovarian cancer and eventually by better outcomes from IP vs.IV cisplatin in randomized studies in patients undergoing optimal surgical debulking at diagnosis.In the past two decades,with the introduction of novel anticancer interventions(such as taxanes,bevacizumab,inhibitors of DNA repair,and immune check point inhibitors),advantages of IP drug delivery are less clear and concerns are raised on cisplatin's therapeutic index.The discovery of BRCA genes and their key role in DNA repair,on the other hand,have strengthened the rationale for IP drug delivery:high grade serous cancers arising in the Mullerian epithelium in association with hereditary or somatic BRCA function inactivation are linked to peritoneal spread of cells that-while initially sensitive-are prone to emergence of platinum resistance.Therefore,selection of patients based on genomic features and focusing on the better tolerated IP carboplatin are ongoing.Recent examples of leveraging the peritoneal route include(1)targeting the cell membrane copper transport receptor-that is shared by platinums-by the combination of the proteasome inhibitor bortezomib and IP carboplatin;and(2)enhancing IP 5-fluoro-2-deoxyuridine cytotoxicity when coupled with PARP inhibition. 展开更多
关键词 Platinum drugs intraperitoneal administration epithelial ovarian carcinoma
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部